

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Mar Tormo *et al.*

Serial No.: 09/381,747

Filed: September 22, 1999

For: INHIBITION OF BCL-2 PROTEIN  
EXPRESSION BY LIPOSOMAL  
ANTISENSE  
OLIGODEOXYNUCLEOTIDES

Group Art Unit: 1635

Examiner: Kimberly Chong

Atty. Dkt. No.: UTSC:550

Confirmation No.: 4363

**CERTIFICATE OF ELECTRONIC SUBMISSION**

DATE OF SUBMISSION: October 18, 2006

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSC:550.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,  


David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: October 18, 2006

Form PTO-1449 (modified)		Atty. Docket No. UTSC:550	Serial No. 09/381,747
List of Patents and Publications for Applicant's		Applicant Mar Tormo <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 22, 1999	Group: 1635
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C195	Kitada <i>et al.</i> , "Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of BCL-2 Gene Expression," <i>Antisense Research and Development</i> , 4:71-79, 1994.
	C196	Tormo <i>et al.</i> , "Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation," <i>Leukemia &amp; Lymphoma</i> , 30:367-379, 1998.

25703515.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.